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Summary 
Necrotizing and crescentic glomerulonephritis (NCGN) is frequently associated with circulating 
antineutrophil cytoplasmic autoantibodies (ANCA).  It is established that ANCA  are specific 
for soluble enzymes of granules of polymorphonuclear neutrophil granulocytes (PMN),  such 
as myeloperoxidase (MPO) or protease 3 (PR3). The purpose of this study was to identify membrane 
proteins of PMNs,  and/or glomerular cells,  as additional autoantigenic ANCA targets. When 
membrane protein  fractions  were prepared  from  PMNs  and  isolated human glomeruli,  and 
immunoblotted with ANCA sera of NCGN patients, two bands with apparent molecular masses 
of 170 and 80-110 kD (gp170/80-110) were labeled in PMNs, and a 130-kD glycoprotein (gp130) 
in glomeruli. GpD0 was purified, and monoclonal and rabbit antibodies (Abs) were produced 
which showed the same double specificity as the patient's ANCA. Using these probes, evidence 
was provided that gp170/80-110 is identical with human lysosomal-assodated membrane protein 
2 (h-lamp-2), because both proteins were immunologically cross-reactive and screening of a cDNA 
expression library from human promyelocytic leukemia cells with anti-gp130 Ab yielded a clone 
derived from h-lamp-2. Gp170/80-110  was localized primarily in granule membranes of resting 
PMNs, and was translocated to the cell surfaces by activation with FMLP. By contrast, gp130 
was localized in the surface membranes of endothelial cells of human glomerular and renal interstitial 
capilLaries,  rather  than  in  lysosomes,  as  found  for  h-lamp-2.  Potential  clinical  relevance of 
autoantibodies to gp170/80-110  and gp130 was assessed in a preliminary trial, in which ANCA 
sera of patients (n =  16) with NCGN were probed with purified or recombinant antigens. Specific 
reactivity was detected in "~90% of cases with active phases of NCGN,  and frequently also in 
combination with autoantibodies specific for PIL3 or MPO. Collectively, these data provide evidence 
that h-lamp-2 in PMNs and a different, structurally related 130-kD membrane protein on the 
cell surface of renal microvascular endothelial cells are autoantigenic targets for ANCA in patients 
with active NCGN. 
R~ 
nal glomeruli are frequently involved in systemic vas- 
culitis, particularly when small blood vessels are affected, 
such as microscopic polyangiitis and Wegener's granuloma- 
tosis (1). Diagnostic criteria for these diseases are their clin- 
ical course, histopathologic patterns in kidney biopsies (1-4), 
and serological markers, especially antineutrophil cytoplasmic 
autoantibodies (ANCA) 1 (5).  In active stages glomerular le- 
1 Abbreviations used in  this paper: ANCA, antineutrophil cytoplasmic 
autoantibodies; GN, glomerulonephritis;  h-lamp-2, human lysosomal- 
associated membrane protein 2; MBP, maltose binding protein; MPO, 
myeloperoxidase;  NCGN, necrotizing  and crescentic  glomerulonephritis; 
PLP, paraformaldehyde-Iysine-periodate;  PR3, prutease 3. 
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sions are characterized by necrosis of single capillary loops 
which are  accompanied by extraglomerular  deposition of 
fibrin, and by proliferation of epithelial cells  of Bowman's 
capsule, causing capsular crescents. Glomerular lesions also 
occur without evidence for systemic disease, and are then desig- 
nated as "idiopathic" (1). 
Although the clinical course and histopathology of ANCA- 
associated diseases vary considerably, they have several fea- 
tures in common which suggest similar pathogenetic roots 
(6).  For example, most diseases show involvement of small 
blood vessels (2), capillary loop necrosis, and crescent forma- 
tion ("segmental and necrotizing glomerulonephritis [GN], 
crescentic GN") (7), rapid clinical progression ("rapid progres- 
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the glomerular lesions ("pauci-immune GN") (2, 8). These 
recent insights have spurred attempts to develop classifica- 
tions of ANCA-associated diseases, resulting in several provi- 
sional consensus nomenclatures (1,  9). 
The discovery of ANCA (10) marks a new era in the study 
of vasculitis, and their serum titer is now an indispensable 
clinical parameter for detection, management, and monitoring 
of vasculitis and/or necrotizing and crescentic glomerulone- 
phritis (NCGN)  (3,  11-14).  The major antigenic targets of 
ANCA  were  identified  as  soluble  enzymes  (15)  of PMN 
granules, such as myeloperoxidase (6, 12), protease 3 (PR3, 
16-18), leukocyte elastase (19),  and others (20-22).  In other 
studies, ANCA autoantibodies to endothelial cells were also 
recorded (23-26),  however their precise antigen specificities 
are controversial. The purpose of this study was to identify 
membrane proteins of PMNs and/or glomerular endothelial 
cells as possible autoantigenic targets for ANCA in NCGN. 
Materials and Methods 
Selection of  Patients and Characterization of  ANCA Sera.  ANCA 
sera of 15 patients with histologically confirmed NCGN were col- 
lected at the time of kidney biopsy, including one transplanted pa- 
tient with recurrence of disease. Classification of the diseases was 
performed according to reference 9. Grading of glomerular capil- 
lary loop necrosis, proliferative changes, sclerosis, and crescent for- 
mation was assessed by two reviewers. We excluded patients with 
vasculitis without kidney involvement, with Churg-Strauss syn- 
drome, or Schoenlein-Henoch's  purpura.  As controls, sera from 
normal healthy subjects  (four female, three male),  and ANCA- 
negative patients with various glomerular and renal diseases (two 
membranous nephropathy, one hemolytic uremic syndrome, one 
focal sclerosis), as well as with NCGN associated with Goodpasture's 
syndrome (one primary disease, and another recurrent in a trans- 
plant) were tested.  All sera were stored  at 4~  in the presence 
of 0.1% azide and 200 IE Aprotinin/ml (Trasylol|  Bayer, Lever- 
kusen). The patient data are listed in Table 1. 
Classification of ANCA patterns was performed by indirect im- 
munofluorescence  on  commercially available test  slides (BIOS, 
Munich, Germany). In parallel, PMNs were isolated by dextran 
fractionation (27, 28) from freshly drawn, heparinized blood, sus- 
pended in  PBS  (5  x  103  PMNs/ml),  and attached onto slides 
(0.2-ml  suspension/slide)  by incubation for 5 min at 20~  fol- 
lowed by fixation in 96% ethanol for 5 min at  -20~  An inter- 
national c-ANCA standard IgG (obtained from the plasmapheresis 
fluid of a patient with Wegener's granulomatosis;  Statens Serumin- 
stitut, Copenhagen, Denmark; 29) was similarly analyzed. Serial 
dilutions of sera (from 1:10 to 1:1280) were screened for Abs specific 
for glomerular endothelial cells, glomerular basement membrane, 
or nuclei by indirect immunofluorescence on unfixed 4-/~m cryostat 
sections of normal adult and fetal human kidneys, mouse kidney, 
and rat liver, using FITC-conjugated F(ab')2 of rabbit anti-human 
IgG (DAKO A/S, Glostrup, Denmark). Antigen specificity and 
titer of ANCA-sera were determined by ELISA, using: (a) a com- 
mercial ANCA system, containing a PMN granule fraction (Anti- 
Neutrophile Zytoplasma Antik6rper ELISA; BIOS),  (b) neutro- 
phil  protease  3  (Anti-PR3  ELISA;  Progen,  Heidelberg);  (c) 
myeloperoxidase  (Anti-Myeloperoxidase  Quantitativer ELISA; BIOS); 
(d) leukocyte elastase in  some cases (kindly performed by Drs. 
E. Csernok and W. L. Gross, Rheumatological Department, Med. 
ical University,  Lfibeck, Germany). 
Membrane Protein Fractions and Antibodies.  Membrane protein 
fractions of isolated PMNs, glomeruli, or placenta were prepared 
by incubation in 200 mM Na2CO3, pH 10.5, and Triton X  114- 
phase partition (30). Murine mAbs were produced (31), using glo- 
merular membrane protein fractions  as antigen. Hybridoma su- 
pernatants were screened by immunoblot analysis using glomerular 
membrane proteins, and by indirect immunofluorescence on isolated 
PMNs and cryostat sections of normal human kidney. Hybridoma 
Ag11 was selected primarily by its similarities to ANCAs of NCGN 
patients, in particular by its ability to immunostain PMNs, as well 
as glomerular and placentary endothelial cells. It was subcloned 
twice by limiting dilution, and maintained in Nutridoma medium 
(Boehringer  Mannheim, Vienna, Austria).  The IgG fraction was 
precipitated  with 50%  ammonium sulfate, and its IgG subclass 
was determined using an isotyping kit (Amersham International, 
Amersham, UK). 
A polyclonal Ab was raised by intradermal immunization of a 
rabbit with 300 #g of electroeluted gp130, suspended in CFA (Difco, 
Detroit, MI), followed by two boosts with 100 #g antigen in IFA. 
Serum samples were collected before immunization, and in weekly 
intervals starting from week three after immunization. Purified 
gp130 was immobilized on CNBr-Sepharose  4B (300/~g/ml; Phar- 
macia LKB, Uppsala, Sweden), and was used to affinity purify anti- 
gp130 IgG from rabbit  and also ANCA sera. 
The use of animals for experimental purposes was permitted by 
the Austrian Ministry of Science. 
Immunoblotting.  Membrane protein  fractions  of PMNs,  glo- 
meruli, or placenta were separated by 7% SDS-PAGE, and trans- 
ferred onto nitrocellulose membranes (Schleicher  and SchueU, Dassel, 
Germany). Immunoblotting was performed as described (32) using 
the following Abs: (a) mAb Ag11 (50 gg/ml); (b) rabbit anti-human 
myeloperoxidase IgG (Calbiochem-Novabiochem  Corp., La Jolla, 
CA); (c) anti-human protease 3 (PR3) Ab WGM2 (kind gift from 
Drs. W. L. Gross and E. Csernok, 33); (d) anti-human lysosomal- 
associated membrane protein (h-lamp-2) monoclonal and polyclonal 
Abs (obtained from Dr. M. Fukuda, La Jolla Cancer Research Foun- 
dation, La Jolla, CA); (e) anti-gpD0 polyclonal Ab; (~ anti-gp130 
polyclonal Ab which was affinity purified on the recombinant fu- 
sion protein of clone 1A1 (see below);  (g) Sera from 15 ANCA- 
positive patients; (h) sera of 7 normal individuals and of 6 ANCA- 
negative patients; (i) commercial ANCA-standard IgG. Appropriate 
alkaline phosphatase-conjugated  IgGs (Promega,  Madison, WI) 
were used as secondary Abs and were detected by NBT-BCIP chro- 
mogenic substrate (Kierkegaard & Perry, Gaithersburg, MD). Dupli- 
cate blots were probed with secondary Abs alone as negative con- 
trols.  Immunoblots  using  patient  sera were  analyzed  by  two 
reviewers and were scored 0 or  +. 
Purification  of Gp130 and Gp170/80-IlO.  Membrane protein frac- 
tions of PMNs, isolated glomeruli, and term placenta were solubi- 
lized in 1% SDS (0.1 mg protein/ml) at 20~  for 30 min with 
sonication,  and adjusted to 1% Triton X-100, 1% sodium deoxy- 
cholate, 0.1% SDS, 0.9% sodium chloride, 20 mM Tris-HC1 buffer, 
pH 7.2 (RIPA-buffer). Solubilized membrane protein fractions were 
sequentially incubated with mAb Ag11 (0.1 mg/ml) at 4~  for 
I h, followed by 300/~1 protein A-Sepharose 4B (Pharmacia LKB) 
for 30 rain. The immune complexes were washed twice in Tris- 
buffered saline, pH 7.2, for 5 rain, and the bound antigen was eluted 
with 1 M glycine-HC1 buffer, pH 2.8, containing 1% Triton X-114, 
at 4~  The eluate was neutralized  with 1 M Tris-HC1  buffer, 
pH 8.0, and concentrated by phase separation of Triton X-114 at 
37~  Proteins in the detergent phase were precipitated with ace- 
tone-ethanol at -20~  separated by SDS-PAGE, and transferred 
onto nitrocellulose membranes. In addition, gp130 was purified from 
586  h-lamp-2  Is an ANCA-antigen Table  1.  Histological Findings in Kidney Biopsies 
Biopsy 
(necrosis/  ANCA 
Patient  proliferation/  (titer 
(sex/age)  sclerosis)  IF-pattern) 
Patient 
(sex/age) 
Biopsy 
(necrosis/  ANCA 
proliferation/  (titer 
sclerosis)  IF-pattern) 
1  H.A.  +/+/+  1:80 
m/69  Cresc 50%  c  +  p 
2 S.A.  +/+/+  1:40 
f/85  Vasculitis  c  +  p 
3 W.E.  + / +/0  1:80 
f/66  Cresc.  40%  c 
granulom. 
vasculitis 
4 L.J.  +/+/+  1:160 
f/66  Cresc. 30%  c 
5 P.P.  +/+/+  1:40 
ff68  Cresc.  60%  c  +  p 
granulom. 
vasculitis 
6 K.S.  + / +/0  1:40 
m/35  Cresc.  60%  c  +  p 
TX 
7 H.A.  +/+/+  1:80 
f/85  Cresc.  20%  c 
8 W.F.  +/+/+  1:160 
m/72  Cresc.  80%  c 
Controls 
17 L.M.  Membranous  GN  neg. 
f/82 
18 E.M.  S-f-GN  neg. 
m/38  sclerosis 
19 B.I.  HUS  neg. 
m/65 
9 B.F. 
m/80 
10 F.M. 
m/58 
11  K.A. 
f/79 
12 S.R. 
f/69 
13 W.L. 
m/47 
14 S.E. 
f/78 
+/+/+  1:80 
Cresc. 40%  c 
+/+/+  1:160 
Cresc.  70%  c 
+ / + / +  1:160 
Cresc.  35%  c  +  p 
granulom. 
vasculitis 
+/+/+  1:40 
Cresc.  10%  c 
granulom. 
vasculitis 
+/+/+  1:80 
C 
+/+/+  1:80 
Cresc.  40%  c 
15  G.F.  +/+/+  1:40 
m/81  Cresc.  40%  c  +  p 
vasculitis 
granulom. 
16 N.N.  Extra-  1:80 
ANCA-stand.  cap.  GN  c 
20 D.B.  Membranous  GN  neg. 
f/48 
21  K.K.  S-f-GN  AGBM 
m/31  Necrosis  1:80 
TX  10%  Cresc. 
22  H.H.  S-f-GN  AGBM 
m/32  Necrosis  1:40 
80%  Cresc. 
c/p, type of immunofluorescence  pattern (cytoplasmic or perinuclear); Cresc., crescents are present (% of glomeruli affected); granulorn., granulomas 
are present; HUS, hemolytic uremic syndrome; Necrosis, necrosis of capillary loops; Proliferation, increase of glomerular cells; S-f-GN, segmental and 
focal glomerulonephritis; Sclerosis, increase of matrix; TX, transplantation;  +/0, present/not  present. 
membrane protein fractions of human placenta by preparative SDS- 
PAGE and electroelution.  Immunoblotting was performed with 
patient  sera,  control sera,  and Abs,  as described  above. 
Molecular Cloning Nucleotide Sequencing of Gp170/80-I10.  A 
)~gll-cDNA expression  library from the  human  promyelocytic 
leukemia  cell line HL 60 (HL 1020b; Clontech, Palo Alto, CA) 
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was screened  (106 PFU)  with  afffinity-purified rabbit  anti-gp130 
Ab. A cDNA clone (1A1) was identified  and sequenced  (32, 34), 
and used to establish  a recombinant fusion protein.  Comparison 
of the nucleotide and amino acid  sequences  was performed by 
searching  the EMBL data bank. 
For expression  of the recombinant fusion protein coded for by clone 1A1 its cDNA was amplified by PCtL from the Xgt11-cDNA 
template, using synthetic oligonucleotide primers with the sequences 
GGGAATTCTTCGGGCCATTGAATGACT (sense)  and  CTC- 
GTCGACCTAAAATTGCTCATATCCA  (antisense).  The  PCK 
product was subcloned into the pCK II cloning vector (TA Cloning 
System; InVitrogen, San Diego, CA), and its sequence was con- 
firmed. The cDNA insert was excised  using an in-frame EcoKI 
site at the 5' end, and subcloned into the maltose binding protein 
(MBP) vector pmal-c (New England Biolabs,  Beverly,  MA;  35). 
The orientation of the cloned cDNA and the integrity of the cloning 
site were confirmed by DNA sequencing.  Synthesis of the fusion 
protein in transformed Escherichia coli DH5a was induced for 2 h 
with 0.3 mM isopropyl-B-D-thiogalactopyranoside  (Sigma Chemical 
Co.,  St.  Louis,  MO). 
SDS-solubilized proteins of induced  and noninduced bacteria, 
as well as electroeluted fusion protein were separated by SDS-PAGE, 
transferred onto nitrocellulose  membranes, and immunoblotted with 
mAb Ag11,  anti-gp130 polyclonal Ab, patient sera, ANCA stan- 
dard serum, all ANCA-negative human sera, monoclonal and poly- 
clonal rabbit anti-h-lamp-2 IgGs, and Abs to MBP (New England 
Biolabs).  The recombinant fusion protein was also immobilized 
on  CNBr-Sepharose  4B  (Pharmacia LKB) and  used  for affinity 
purification  of polyclonal rabbit  anti-gp130 serum (32). 
Immunohistochemistry.  Unfixed 4-gin-thick cryostat sections of 
surgical specimens of normal human kidney, lung, nasal and laryn- 
geal mucosa, skin, liver, stomach, pancreas, small intestine, lymph 
node, spleen, term placenta,  and umbilical cord were incubated with 
mAb Agll IgG (10 #g/ml), followed by FITC-conjugated F(ab')2 
fragment rabbit anti-mouse IgG (Accurate Chemicals, Westbury, 
NY). 0.5-gin frozen sections were cut from a paraformaldehyde- 
lysine-periodate (PLP)-fixed normal human kidney,  and isolated 
PMNs, on a Reichert Ultracut ultramicrotome (Vienna, Austria) 
with F4 cryo-attachment (36).  Binding of mAbs Agll or anti-h- 
lamp-2  was  visualized  by  indirect  immunofluorescence,  using 
TKITC F(ab')2  rabbit  anti-mouse  conjugates  (Accurate  Chem- 
icals),  or by avidin-biotin immunoperoxidase method (StrAviGen 
Super Sensitive Universal Immuno-staining Kit; BioGenex Labora- 
tories, San Ramon, CA). Slides with isolated PMNs were similarly 
stained by indirect  immunofluorescence with  the mAbs.  HL 60 
cells (American Type Culture Collection,  Kockville, MD) before 
Figure  1.  Identification of gp130 as antigenic target of ANCA sera  and 
of the mAb Ag11 in isolated human glomeruli. Fractions of glomerular 
membrane proteins were separated  by SDS-PAGE, transferred  onto nitrocel- 
lulose membranes, and probed with a series of Abs. Lane I, mAb Ag11; 
lane 2, international ANCA standard IgG obtained from the hemofiltrate 
of a patient with Wegener's granulomatosis; lane 3, serum of patient no. 
9; lane 4, serum of patient no. 2; lane 5, serum of patient no. 15. The 
proteins labeled in lower intensity in lanes 2-5 besides gp130 were also 
observed in controls with ANCA-negative sera, and are therefore consid- 
ered background labeling. 
and after stimulation with  1.25% DMSO  for 10 d  (37),  as well 
as bone marrow smears from normal individuals and from promye- 
locytic leukemia patients, were cytocentrifuged onto slides, fixed 
in 96%  ethanol,  and also processed by the avidin-biotin system. 
Ultrathin frozen sections of PLP-fixed  normal human kidneys 
or isolated, pelleted PMNs were prepared as described (38).  Sec- 
tions were incubated with mAb Agll (10 #g/ml), a bridging affinity 
purified rabbit anti-mouse IgG, followed by goat anti-rabbit IgG- 
10 nm gold conjugate (1:20, Auroprobe; Amersham Corp.). In some 
experiments, freshly isolated PMNs (2  x  106 ceUs/ml HBSS) were 
Figure  2.  Specific  binding of ANCA sera  to recom- 
binant fusion protein 1A1 (derived from h-lamp-2), 
or to purified gp130. The fusion protein 1A1 was pre- 
pared from a clone derived from a )~gtll expression 
library of human promyelocytic  leukemia cells which 
showed sequence homology to h-lamp-2. Gp130 was 
aifinity purified with mAb Ag11 from a membrane 
protein fraction of human placenta. Immunoblots of 
(A) recombinant MBP-fusion protein  1A1, and (B) 
purified endothelial 130-kD Agll membrane protein 
were incubated with the following primary Abs, and 
detected with  alkaline phosphatase-conjugated sec- 
ondary Abs: lanes  A  1-3, negative  controls, using (lane 
1) sheep anti-human  IgG-alkaline phosphatase con- 
jugate only, (lane 2)  sheep anti-rabbit  IgG-alkaline 
phosphatase conjugate, and (lane 3)  serum from a 
healthy human subject; lane A 4, mAb Agll as pri- 
mary Ab; lane A 5, rabbit anti-MBP Ab; lane A 6, 
rabbit anti-gp130 IgG; lane A  7, ANCA standard IgG; lane A 8, serum of patient no.  15; lane A 9, serum of patient no. 2; lane A  10 rabbit anti- 
h-lamp-2 IgG; lane B I, mAb Ag11; lane B 2, rabbit anti-gp130 IgG; lane B 3, ANCA standard IgG; lane B 4, serum of patient no. 2; lane B 5, 
serum of patient  no.  15. The ,x,50-kD band at the bottom of the lanes is derived from mAb Ag11, and is also found in control experiments. 
588  h-lamp-2 Is an ANCA-antigen Figure 3.  Glomerular  endothelial  staining  pattern (arrowheads), obtained 
by indirect immunofluorescence  with the ANCA serum of patient no. 
9 (specific for gp130 only, see also Fig. 1, lane 3) in a cryostat section 
of a normal human  kidney.  (AA) Afferent  arteriole; (C) capillary  lumen. 
x400. 
for their antigen specificity by immunoblotting and ELISA. 
A synopsis of the data is presented in Table 2. Collectively, 
ANCA sera were divided into four categories: (a) sera specific 
for gp130 only, with c-ANCA pattern, and mostly with re- 
activity with endothelial cells (25% of  our patients); (b) sera 
with double specificity to gp130 plus to PP,.3, with c-ANCA 
pattern, and mostly labeling endothelial cells (25%); (c) sera 
with exclusive reactivity with PR3,  expectedly showing a 
c-ANCA pattern and no reactivity with endothelium (12.5%); 
and  (d)  sera  with  mixed reactivity for  gp130  and  MPO, 
showing a "mixed c+p ANCA" pattern and mostly binding 
to endothelial cells (37.5%). Among the ANCA sera in this 
preliminary study no "pure" p-ANCA pattern was observed, 
and no serum was found which exclusively reacted with MPO 
(Table 2). 
The mixed c+p ANCA pattern consisted of variable com- 
binations of granular and speckled perinuclear,  cytoplasmic, 
and/or cell surface labeling (Fig. 4, A  and C), and was par- 
ticularly obvious  when  PMNs  were  attached  onto  slides 
without cytocentrifugation. This mixed ANCA pattern was 
incubated in 10 -6, 10-7, and 10 -s M FMLP (Sigma  Chemical Co.) 
for 15 and 30 min at 37~  before fixation in PLP. 
Results 
Imrnunoblotting of  Patient Sera.  When membrane protein 
fractions of glomeruli or placenta were immunoblotted with 
ANCA sera of 15 patients with NCGN and with ANCA 
standard IgG (listed in Table 1), two sera (no. 2 and 15) strongly 
reacted with a band of apparent molecular mass of 130 kD 
which was provisionally designated gp130.  Other sera (no. 
1,  3-9,  and  11-13) and the ANCA-standard IgG (no.  16) 
showed weaker labeling, while two sera (no. 10 and 14) failed 
to bind gp130  (Fig.  1).  All sera used,  including ANCA- 
negative control sera, produced weak unspecific binding to 
several other variable proteins (Fig. 1). Affinity-purified  gp130 
was specifically labeled by two selected sera (no.  2 and 15), 
and by ANCA standard IgG (Fig.  2 B, lanes 3-5). Control 
sera from normal humans and patients with ANCA-unrelated 
renal diseases consistently failed to bind gp130 (not shown). 
When the sera of patients no. 2, 6, and 15 were fractionated 
on a gp130 affinity column, the resulting gp130-binding IgG 
fractions specifically immunoblotted to the recombinant fu- 
sion protein derived from cDNA clone 1A1  (not shown). 
Immunoblots with ANCA sera on membrane protein frac- 
tions of isolated human PMNs labeled a sharp band at 170 
kD and an additional broad band at 80-110  kD (provision- 
ally designated gp170/80-110).  However, they also showed 
a high background labeling of other variable proteins.  Similar 
findings were obtained when immunoblotting was performed 
on enriched preparations of gp170/80-110  (not shown). 
ANCA,  Antiendothelial  Antibodies,  and  Reactivity  with 
GpI30.  The ANCA pattern of sera from 15 patients with 
NCGN, and ANCA standard IgG were classified by indirect 
immunofluorescence  on PMNs. ANCA sera were also charac- 
terized for their reactivity with endothelial cells (Fig. 3), and 
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Table  2.  Correlation of ANCATattern with Type of Antigen 
Patients 
c-ANCA 
AG11/ANCA/PR3/ 
MPO/endothelium 
Mixed c  +  p ANCA 
AG11/ANCA/PR3  / 
MPO/endothelium 
I 
3 W.E. 
7 H.A. 
8 W.F. 
9 B.F. 
II 
4 LJ. 
12 S.R. 
13 W.L. 
16 X.Y. 
III 
10 F.M. 
14 S.E. 
IV 
1 H.A. 
2 S.A. 
5 P.P. 
6 K.S. 
11 K.A. 
15 G.F. 
+/010/0/0 
+/0/010/+ 
+/0/0/0/+ 
+/0/0/0/+ 
+/+10/0/0 
+/+/+/0/+ 
+/+/0/0/+ 
+1+/+101+ 
O~ + / +/0/0 
O~ + / +/0/0 
m 
m 
m 
D 
m 
m 
D 
m 
m 
m 
+/0/0/+ / + 
+/0/0/+ / + 
+/0/0/+ / +- 
+/0/0/+ / + 
+/0/0/+ / + 
+/0/0/+ / + 
Categories of different  patterns of ANCA staining: (/) Sera specific  for 
gp130 only; (I/) sera which contain  antibodies to gp130 and in addition 
also to PR3, and/or are positive in the ANCA-ELISA;  (III) sera which 
reacted exclusively  with PR3; and (IV) sera with mixed reactivity  with 
gp130 and MPO. Figure 4.  Effect  of  different 
methods of PMN preparation on 
the patterns of ANCA labeling on 
human PMNs by indirect immu- 
nofluorescence. PMNs were iso- 
lated by dextran fractionation, and 
were allowed to attach to micro- 
scopic slides  (.4 and C), to be com- 
pared  with  PMNs  attached by 
cytocentrifugation (B and D), be- 
fore fixation  with ethanol. Sera 
used were from patient no. 2, with 
double specificity for MPO  and 
Ag11 antigenic proteins (A and 
B), and from patient no.  1, with 
the same double specificity (C and 
D). (/1) A mixed staining pattern 
is observed which shows a typical 
perinudear labeling, characteristic 
for the p-ANCA pattern (p), and 
speckled membrane staining (ar- 
rowheads),  combined with a cyto- 
plasmic  staining resembling the 
c-ANCA pattern. There is great 
variability  in the patterns among 
the PMNs. (B) A typical perinu- 
clear p-ANCA  pattern in high (p), 
or lower intensity (arrowhead)  pre- 
vails among PMNs.  (C) In this 
example a similar staining to A 
can be  detected,  whereas  the 
same serum in D  stains more in 
a  c-ANCA pattern.  Note,  that 
sometimes the nucleus is covered 
by a "haze" of fluorescence (arrow- 
heads),  which is frequently found 
when Abs to MPO and Agll anti- 
genic proteins are combined, but 
not in c-ANCA sera specific only 
for PK3 and/or Ag11 antigenic 
proteins.  C, Eosinophilic granu- 
locyte,  x400. 
similar to that observed when  mAbs specific for gpl30  and 
MPO  were combined for indirect immunolabeling of PMNs 
(not  shown). 
Characterization of Monoclonal Agll  and Rabbit Anti-gpl30 
Antibodies.  mAb  Agll  (IgG2~ subclass) was obtained from 
a mouse that was immunized with a preparation of glomer- 
ular membrane proteins,  mAb Ag11 was selected because it 
showed  the  same  specificity as natural  ANCA  sera,  in that 
Figure 5.  Identification of membrane protein antigens of the mAbs Ag11 
and anti-h-lamp-2 in several tissues, obtained by immunoblotting on mem- 
brane protein fractions of human glomeruli (lane  I), placenta (lane 2), 
PMNs (lane 3), and purified mAb Ag11 antigenic proteins from PMNs 
(lane 4).  This Ab is specific for a 130-kD  protein (gp130) in glomeruli 
and placenta, and it binds to a 170 and a 80-110-kD proteins (gp170/80-110) 
in PMNs. (Lanes 5-7) Immunoblots with mAb anti-h-lamp-2, using the 
same protein preparations as in lanes 1-3. In glomeruli (lane 5) this mAb 
binds to gp130 and additionally to a 100-kD protein which is not recog- 
nized by the Agll Ab. In placenta (lane 6) the mAb anti-h-lamp-2 binds 
predominately to a ,-110-kD protein, and in very low intensity also to 
the 130-kD  protein. In PMNs (lane 7) essentially the same proteins are 
labeled as with the Ag11 Ab. The "~50-kD protein in lane 4 is derived 
from mAb Ag11 which was used to purify the antigen of PMNs. 
590  h-lamp-2 Is an ANCA-antigen Table 3.  Comparison  of the Partial Sequences of h-larap-2 and the ACll-antigen 
EXON  4  {partial)  ..... 
1  GIIJkT  T CO(~X~CJkTTOAJ~'I'~ Ct:l  TVI "t AOAT(~d~ATAO'I"I~ATC~d~CT'I'TG~;~IkAG/d~TC~'D3"I'rOTCCAA  CACTACTGGG&TG~ ~TA ~Gt-i-11  l~r  CCAAAATOGCACAGTGAGCACAAATG  12 7 
IIIII .... ~~~]~~~~~~~~ 
130  aGIULTT.... CCATTGJ~D,  TGAC~ ~ 1 ~ a ~AGATGCDJkTAGTTTATCJ~A(2TI'rGG/U~AGAA~3AT(~'I~TC~A~~TA~O~  111~C~~&~-  .......  256 
Olu PheQ1 v p r oLeuAanAspLQu PheArgCy￿9  er  LeuS e~,~Thr  LeuO  1  uLymAmr~mpVa  1  Va 1OlnHs  1  LeUVa 1G1 hal a PheVa  1Ol  has  nOlyThr Va  1  Sel~rhrAe  n 
ArgIle 
EXON  S 
127  g AGTT C~TGAT~It  GGA~ C'I'r CJUt.CJt.GTG(3CACCCA CCATA CJ), CA  CCACTOTGCCA TCTCCTAC'rAC~  ~C~A~C  C~C~G~C~A~T~TA~  267 
~1~ii~iii1~i~.i~i~i~i~t~I~~~i1~i~i~ti~i~ii~ii~ii1~i~i~ii~i~iii1~iiiiiii~ 
229  gAG`~T~CT~T~T~&TAkAC~A~C~C~AC&~T~C.~C&CCATACACA~CACTGH`~CCATCTCCTACTACA~C&~A~~C~C~A~T~TA~  36~ 
GI u Phe LeuCymA￿9149149  erThrVa  l&l ￿9 P r  oThr  I I ￿9  s ThrThr  v a 1 Pros  ￿9 r P roThrThrThr  ProThr  Pr o Ly ￿9  1 uLy￿9 Pr oG lu~d~GlyThz~yrSerV￿9 
....  Pro 
268  C'TGCTGGC'r  AC  CATC.GGGCFQC/kO C'FOA~ CATCACTC~GGATAAG  312 
IIIl*'llfllllllllllllllllllllllllllllllllllll 
)70  ~GTG~'~A  CCATG~G  C'/~CA(~A~  C~TC~qC'~C~AT~G  414 
LeuLeuAl  aThrMe  t Ol yLeuGlnLet~Bn  I l ￿9  r~lpbyr 
EXON  6 
313  GI~'GCTTCAG~TTAACATCA~CCCCkATAC.AA  CT  CACTC  CAC.AGGCAGCTGCCG~CA~A~AG  A~ T~GCAGC~ CCA~TAT~A~~  415 
i~i~i~i~~~ii~ii~i~i~i~i~~i~ii~Ii~~~)i 
175  G~C~CAGTTATTAD,  CATCAACCCCAATACAACTCACTC  CAC.AGG  CAG  CTGC  ~~A~A~TAG~  O  ~C ~GTAT~A~~  217 
Va  I  AI  aS￿9 V￿9  111  e  A￿9  ~  IeAe  nPr  oAsnThrThrHim S  e  rThrG  I  u  r  Cy￿9  ￿9  &Le~LeuA-~C3LeuAe~.q  e  r  S  e  rTh  r  I  l  eLyeTyrLeuAmp PheV￿9  Phe~l  ￿9  1 
EXON  7  .... 
436  AAAAAT~C  CGAqI"I~'ATCTGAAGGAAGTGAA CATCAGCAT~TA ~-r  GG  ~F/'AATr.,G~C~  4~9 
llllIl]lilllllllllllllllllIlillllllillIIlilIlllllllllliliillllll 
203  AAAAATGAAAAC CGA]'TI~'ATCTGAAGGAAGTGAACATCAGCATGTA~['I~GG~'T  AATGGCTCCG  266 
LymA￿9149149149 
EXON  8  .............. 
499  g~ CAGCATTGCAAATAACAATCTCAGCTACTGGGATGCCCCCCTGGG  AAQT~C~TATATGTGCAA~~  C  AGTGT~A~GAT~TAC~AT~~T  639 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
126  g~CAGC.A~I~AAATAACAATCTCAGCTACM[~GGATGCCCCCCTGGGAAGI~"  CS[TATATGTGC2kA~GA~~~T~TA~T~~T  266 
V  a  I  P  heSer  I  i  eAl  aA￿9149  hA￿9  nLe  uSerTyrTrpA￿9  ￿9  P  r  oLeuOl  y￿9  er  S  e~/rMet  CymA￿9149  u  G1  nThrV￿9  i  S  ￿9  r  Va  i  S  e  rGl  yAI  ￿9  PheGl  nl  i  eAmnTh~PhsJ~￿9149  IG~nProPheAen 
640  GTGACA CAAGGAAAGTATTCTACAG  664 
I11111111111111111IIIIIII 
2G7  GTGACA  CA~GGAAAGTATT CT~C3~G  251 
Va  IThrG  InOl  yLysTyr  S  ￿9  rThr 
EXON  9  .......... 
664  ~  CT  CAAGA  CTGCACTG CAGATt;AC~G~CAACI~'CCTTGTGCC CATAG  CO<~TGGGAG  CT~C~GGAGTA~A~AG~  ~A~A~Q~  C~T~TA~AO  804 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••[•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••1111111111•••••••••• 
188  g  CT~AAGACTGCAGT~A~ATGAc~&CAAcTT~cTTGT~CATTGCGGTGGOA~CTc.~GGAGT&~A~A~~A~A~~T~T&~A~  32S 
A  1  aG  ]  ru%mpC),mThrA1  aA￿9149  I  Pro  la~A  IaVa  iO  1  yAl  aAl  aLeuAl  ~GIyV￿9  1  Leu  I  1  eL  euVa  1  Le~  l~euA1  a  Tyr  Phe  I  1  ~yLeuLyiH~iH~l  ￿9  mAI  aOl  yTT~luOl  n  Phe* 
Set 
Upper lane: sequence  of Agll antigen;  lower  lane: sequence  of h-lamp-2. These  sequence  data are available  from EMBL/GenBank/DDBJ  under acces- 
sion numbers LO9709-L09717. 
it labeled spedfically glomerular and placentary gpl30 by im- 
munoblotting (Figs. 1, lane 1, 2 B, lane 1, and 5, lanes I 
and 2),  and gp170/80-110  in PMNs (Fig. 5, lane 3).  The 
antigen specificity  of mAb Agll was apparently different from 
PI%3 (molecular mass 29 kD), and MPO (•60  kD). 
Polyclonal rabbit Ab obtained by immunization of a rabbit 
with purified gp130 showed the same characteristics as mAb 
Agll by immunoblotting (Fig. 2 B, lane 2), and by immuno- 
histochemistry (not shown). 
Identification of  Gp170/80-110  as  h-lamp-2 of PMNs. 
Screening of a kgt11-cDNA expression library of HL60 cells 
with affinity-purified polyclonal gp130 IgG identified a done, 
designated  1A1, with extensive homology to  the human 
lysosomal membrane protein, h-lamp-2, both at the nucleo- 
tide and predicted amino acid levels (Table 3). cDNA of 1A1 
coded for the entire cytoplasmic and transmembrane domains 
of h-lamp-2 and for 231  amino acids of the extracellular 
domain. 
A 1Al-derived recombinant MBP fusion protein (37 amino 
acids of the cytoplasmic and transmembrane domains,  and 
231 amino adds of the extracellular domain) was expressed, 
which bound rabbit anti-gp130 IgG (Fig. 2 A, lane 6), but 
not mAb Agll (Fig. 2 A, lane 4). This fusion protein was 
specifically labeled by ANCA sera of patients  no. 3, 6, 13, 
and 15, and by ANCA standard IgG. Weaker labeling was 
detected by sera of patients no. 1, 2, 4, 7, 8, and 11 (examples 
are given in Fig. 2 A, lanes 7-9). 
When rabbit  anti-gp130 Ab was affinity purified,  using 
recombinant fusion protein of clone 1A1, it was found to 
immunolabel purified gp130 (not shown). Expectedty, 1A1 
fusion protein was also labeled by rabbit  Ab specific for h- 
lamp-2 (Fig. 2, A, lane 10). No binding was observed with 
control Abs (Fig. 2 A, lanes I-3), and monoclonal anti-h- 
lamp-2  IgG. 
Immunoblotting and Imraunohistochemistry  with Anti-h-lamp-2 
Antibodies.  An anti-h-lamp-2 mAb specifically immuno- 
blotted gp130 prepared from membrane protein fractions of 
human glomeruli, similar to mAb Agll (Fig. 5, lanes 1 and 
5). In samples prepared from placenta, anti-h-lamp-2 Ab de- 
tected an additional  protein with apparent  molecular mass 
of 110 kD which was barely labeled by mAb Agll (Fig. 5, 
lanes 2 and 6). In preparations  of PMN membrane proteins 
monodonal h-lamp-2  Ab reacted with gpl70/80-100,  i.e., 
the same proteins  as mAb Agll (Fig.  5, lanes 3 and 7). 
In 0.5-/~m thick frozen sections of normal human kidney 
(Fig. 6, B) and isolated PMNs (not shown) anti-h-lamp-2 
mAb labded exclusively lysosomes of all cells in a granular 
pattern. 
Localization of Gp130 in Kidne  7 and Other Tissues.  Endo- 
thdial cells of glomeruli and of interstitial capillaries, but not 
591  Kain et al. Figure  6.  Comparative localization of antigens of mAbs Agll (A) and anti-h-lamp-2 (B) by indirect immunofluorescence  on consecutive 0.5-#m- 
thick frozen sections of normal human kidney.  (A) Ag11 labels surface membranes of endothelial cells in glomeruli (E), as well as interstitial capillaries 
(Cap), and also some trapped PMNs. (B) anti-h-lamp-2 mAb labels lysosomes of glomerular endothelial and epithelial cells (GEC), as well as of epithelia 
of Bowman's capsule,  proximal tubules (PT),  and interstitial capillary endothelium (Cap). (CL) capillary lumen;  (BC)  Bowman's  capsule  x400. 
592  h-lamp-2 Is an ANCA-antigen Figure 8.  Localization  of gp130 
in human glomerular endothelial 
cells by  immunogold  labeling 
with  mAb  Ag11 on  ultrathin 
frozen sections. (A,  B,  and  C) 
Gold particles (arrowheads)  bind 
exclusively  to surfaces of glomer- 
ular endothelial cells (E), where 
they are concentrated at the lu- 
minal surfaces  in a patchy  pattern. 
Occasionally antigen is also de- 
tected at the abluminal side of  en- 
dothelial cells, and close to inter- 
cellular  junctions O). There is no 
specific  labeling  of  glomerular  ep- 
ithelial cells (GEC), of the base- 
ment  membrane (GBM), or of 
extensions  of  a  mesangial 
cell (MES) in C.  (US) Urinary 
space, x 18,000. 
of arteries and arterioles, were specifically labeled by immuno- 
histochemistry using  mAb  Ag11,  as  most dearly observed 
in 0.50-/zm-thick frozen sections of normal human kidneys 
(Figs. 6 A  and 7 A). Specific and selective endothelial staining 
was  also observed in the capillaries  of placenta,  and  in the 
brush borders of kidney proximal tubules (Fig. 7 A). In ad- 
dition, bile canaliculi,  type I pneumocytes, and the epithe- 
lium of stomach and small intestine were labeled (not shown), 
but  no  other  organs  (heart,  lymph  node,  umbilical  cord, 
skin,  skeletal muscle, laryngeal mucosa, and pancreas). Both 
mAb Agll and rabbit anti-gp130 Ab failed to label unstimu- 
lated  and  IL-l-treated  cultured  human  umbilical  cord en- 
dothelial cells, and they did not cross-react with several tissues 
from rat,  mouse,  and  monkey  (not  shown). 
By immunoelectron microscopy, mAb Agll exclusively la- 
beled the endothelial cell membranes  of human  glomeruli, 
predominately on the luminal  side,  and,  to a lesser extent, 
also  on  the  abluminal  plasmalemma  (Fig.  8).  Intracellular 
staining  was  not  observed. 
Localization  ofgio170/80-I10  in PMNs and Related Cells. 
PMNs which were entrapped within glomerular capillary loops 
intensely bound mAb Ag11 (Figs. 6 A  and 7 A). mAb Ag11 
produced a granular cytoplasmic c-ANCA pattern in isolated 
human PMNs by indirect immunofluorescence (Fig.  9 A). 
By indirect immunogold electron microscopy on ultrathin 
frozen sections of unstimulated, freshly isolated PMNS, most 
gold particles were found on membranes of granules, but also 
in small patches on the cell surface. The intra- and extracel- 
lular distribution of gold particles was quantified (Table 4), 
and found to increase towards the surface localization by more 
than fourfold when isolated PMNs were stimulated by FMLP 
(Fig.  9,  B  and  C). 
In bone marrow smears, mAb Agll immunolabeled cells 
of the promyelocytic stage, but no earlier forms of the my- 
Figure  7.  Immunohistochemical  localization gp130 in 0.5-/zm-thick frozen sections  of a normal human kidney (A), and in DMSO-activated HL-60 
cells (B), using mAb Agll and an avidin-biotin peroxidase  method. (A) Within the glomerulus Ab labels exclusively  endothelial cells, as well as some 
trapped PMNs. In the interstitium, endothelial cells of the capillaries (Cap), but not of a small artery (Art) are specifically  labeled. There is also binding 
to the brush border region of  proximal  tubuli (PT). (B) The mAb Agll labels specifically  granules  of  DMSO-activated  HL 60-cells. (A) x 400; (B) x 630. 
593  Kain et al. Figure 9.  Localization  of the membrane  protein gp170/ 
80-110 on freshly isolated and activated human PMNs. 
(A) Indirect  immunofluorescence  on a 0.5-#m-thick frozen 
section of isolated PMNs with mAb Ag11. Granular cy- 
toplasmic staining (arrowheads)  is resolved  at high magnifi- 
cation. (/3)  Immunoelectron  microscopy  on ultrathin  frozen 
sections of PMNs, 10 rain  after exposure to  10 -6 M 
FMLP. The number of gold particles is greatly enhanced 
when compared to nonactivated PMNs in C, as quanti- 
tated in Table  4. A granule is encountered in the process 
of  exocytosis  (arrow). Note the 10-nm  gold particles  both 
on the cell  surface  (arrowheads),  and on granule  membranes. 
(C) A granule (arrow) in the state of exocytosis  which 
delivers Agll antigens at the cell surface. (A)  x400; (B 
and C)  x18,000. 
dopoietic lineage. In promyelocytic leukemia, intense granular 
staining of the tumor cells was observed (not shown), similar 
to the promyelocytic leukemia cell line HL-60, especially after 
induction of differentiation by DMSO (Fig. 7 B). Monocytes 
and  lymphocytes were not  labeled. 
Discussion 
Necroses of single glomerular capillary loops and/or for- 
mation  of capsular  crescents are histopathologic  hallmarks 
of NCGN.  Development of these lesions involves, presum- 
ably, damage of glomerular endothelial cells and release of 
toxic products by activated immobilized PMNs,  and could 
be related to the occurrence of ANCA (reviewed in reference 
39). Since presentation of autoantigenic protein(s) on cell sur- 
faces to circulating ANCA  could be a central pathogenetic 
event (39-41) the question arises whether integral membrane 
proteins of PMNs and/or glomerular endothelial cells could 
serve as targets for ANCA.  In this study we have identified 
gp170/80-110 in PMNs which specifically react with ANCA 
sera of patients with NCGN.  Unexpectedly, these sera also 
594  h-lamp-2  Is an ANCA-antigen 
cross-reacted with  an endothelial membrane protein of the 
renal microvasculature, provisionally designated as gp130. A 
mAb and rabbit polyclonal Ab with double specificities for 
gp130  and  gp170/80-110  as  the natural ANCA  were used 
to further characterize the biochemical nature of the autoan- 
cross-reacted with  an endothelial  membrane protein of the 
Tabh  4.  Q~antification of ACIl-anti~ens  on the Surface 
Membrane of Normal  and Activated PMNs 
Gold particles 
Number  per #m 
of PMN  #m counted  membrane 
Not stimulated  22  130  1.5  _+ 1.9 
FMLP 
stimulated  22  126  5.4  +  2.8 
The difference  of the number of gold particles per #m membrane  between 
the control and the stimulated group is highly significant  (p >0.0001, Stu- 
dent's t test) renal microvasculature, provisionally designated as gp130. A 
mAb and rabbit polyclonal Ab with double specificities for 
gp130 and gp170/80-110  as the natural ANCA were used 
to further characterize the biochemical nature of the autoan- 
tigenic membrane proteins, to define their localization, and 
to examine their possible clinical  relevance. 
Several results provided evidence that gp170/80-110 is iden- 
tical with h-lamp-2 of PMNs. This conclusion was based on 
the findings that gp170/80-110  specifically reacted with a mAb 
to h-lamp-2, its amino acid sequence was identical with that 
of h-lamp-2,  it  was localized in the membranes of PMN 
granules,  and anti-h-lamp-2  Ab  and  anti-gp130  IgG  im- 
munolabeled the same membrane proteins in HL-60 cells. 
The major lysosomal membrane glycoproteins from human 
and other species (42-46) are transmembrane proteins with 
extensive and unique glycosylation, and they were thought 
to protect lysosomal membranes from degradation by enzymes. 
It is now established that h-lamp-2 is the prototype of a rap- 
idly growing family of structurally related glycoproteins (leu- 
kosialin [47] lamp-l, lamp-3 [CD63], and limp II [reviewed 
in reference 45]) which shows a wide range of diverse func- 
tions, including pathological processes, such as formation of 
metastasis of colonic carcinoma (48) and increased PMN sur- 
face expression in scleroderma (49). Gp170/80-110  is primarily 
a resident of granule membranes in PMNs, but is inserted 
into the plasma membrane by exocytosis during PMN acti- 
vation, as determined by quantitative immunocytochemistry. 
Similar relocations are known for other granule membrane 
proteins, such as Mac-l, LFA-1, and p150/95  (50) or lgp-A 
(51), and for h-lamp-2 in activated platelets (52). Thus, acti- 
vation of PMNs could expose large amounts of gp170/80--110 
on their surfaces,  and make them available  for binding of 
ANCA in vivo and in vitro. Since lamp-related glycoproteins 
were recently identified as counter-receptors for selectins which 
are essential for attachment of inflammatory cells  to  en- 
dothelium (45, 53), it is possible that ANCA sera which con- 
tain anti-h-lamp-2 Abs interfere with this process. 
Current concepts of the pathogenesis of glomerular lesions 
in NCGN postulate exposure of ANCA antigens on the sur- 
faces of PMNs and endothelial cells (39).  A major obstacle 
for these hypotheses so far was lack of expression of respec- 
tive antigens on endothelial cells in vivo. Here we report that 
the ANCA antigen gp130 is expressed selectively on microvas- 
cular endothelial cell surfaces in human kidneys in vivo (and 
in vitro, our unpublished data). This localization could ac- 
count for the concentration of microvascular lesions to glo- 
merular capillaries,  and explain also the occurrence of anti- 
endothelial Abs in NCGN. 
To establish a relation between gp130 and h-lamp,  Abs 
against both proteins were tested for their cross-reactivity 
by immunopurification. Polyclonal anti-gp130 Ab, purified 
on recombinant fusion protein from clone 1A1 yielded an 
IgG fraction that immunostained the same structures as Abs 
against h-lamp-2. Since gp130 reacted with Abs to h-lamp-2 
by immunoblotting, it was intriguing that it was localized 
at the endothelial cell surfaces rather than in lysosomal mem- 
branes where h-lamp-2 is located. One possible  explanation 
is that the 130-kD antigen is structurally not identical with 
h-lamp-2, that it shares only one or several epitopes, and that 
it is directly targeted to the cell surfaces of endothelial cells. 
Another simple explanation is that the 130-kD membrane 
protein is an isoform of h-lamp-2 which differs primarily in 
its carbohydrate side chains, and that mAb Ag11 is specific 
for epitopes that are available on endothelial cell surface only. 
Distinction between these explanations will be possible when 
the complete amino acid sequence and structure of carbohy- 
drate side chains of the 130-kD membrane protein will be 
known. 
Close association of ANCA with diseases causing NCGN 
is now well established (3).  Types of ANCA patterns ob- 
tained by indirect immunofluorescence on PMNs, and pres- 
ence of Abs to MPO or PK3 were found to correlate with 
the type of the underlying disease, and with the activity of 
NCGN (3, 39, 40). In a preliminary trial we have assessed 
the frequency at which ANCA sera of patients with NCGN 
contained IgG specific for gp130 and gp170/80-110 and we 
found that 14 out of 16 contained such Abs. The presence 
of these Abs also correlated with the histopathology of kidney 
biopsies, in that they were exclusively associated with recent, 
necrotizing glomerular lesions. Selected ANCA sera were also 
purified on affinity columns containing gp130 and were shown 
to bind to the recombinant fusion protein of the h-lamp-2-de- 
rived clone 1A1, thus confirming specific reactivity of ANCA 
with h-lamp-2. In addition, the combined immunoblotting 
and ELISA findings indicated that a relatively large propor- 
tion of ANCA sera contained a mixture of Abs specific for 
gp170/80-110 and gp130,  plus for MPO or PR3. 
Collectively, the results of this study establish a novel role 
for h-lamp-2 as autoantigenic targets of ANCA in PMNs, 
and for a structurally related, immunologically cross-reactive 
130-kD endothelial membrane protein in renal glomeruli. Lo- 
cation of these membrane proteins on the cell surface raises 
the intriguing possibility that they could contribute to cell 
activation by ANCA, and to direct cross-linking of PMNs 
to glomerular endothelial cells. 
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